There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Avalo Therapeutics Inc. (AVTX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.005, or 4.05%, to $0.1284. The Avalo Therapeutics Inc. has recorded 3,377,592 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Avalo Enters into Agreement to Divest AVTX-800 Series.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.12 and fluctuated between $0.1425 as its day high and $0.1150 as its day low. The current market capitalization of Avalo Therapeutics Inc. is $12.53M. A total of 85.41 million shares were traded on the day, compared to an average of 23.98M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, AVTX has seen 1 BUY and 3 SELL insider trades, representing the acquisition of 2,000 and the disposition of 2,545,404 shares. Over the last 12 months, there were 35 BUYs and 3 SELLs from insiders. Insiders purchased 211,257 shares during that period but sold 2,545,404.
In the most recent transaction, ARMISTICE CAPITAL, LLC sold 937,404 shares of AVTX for 0.52 per share on Jun 27. After the transaction, the 10% Owner now owns 731,458 company shares. In a previous transaction on Jun 26, ARMISTICE CAPITAL, LLC sold 2,746,138 shares at 0.61 per share. AVTX shares that 10% Owner owns now total 1,668,862.
Among the insiders who bought shares, Caissa Capital Management ltd. acquired of 2,000 shares on Jun 20 at a per-share price of $4.14. This resulted in the 10% Owner holding 1,425,700 shares of AVTX after the transaction. In another insider transaction, Caissa Capital Management ltd. bought 3,000 shares at $3.90 per share on Jun 16. Company shares held by the 10% Owner now total 1,423,700.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for AVTX in the last 3 months, the mean price target is $0.75 with high estimates of $0.75 and low estimates of $0.75. In terms of 52-week highs and lows, AVTX has a high of $7.00 and a low of $0.08.
As of this writing, AVTX has an earnings estimate of -$1.1 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$1.1 per share and a lower estimate of -$1.1. The company reported an EPS of -$0.85 in the last quarter, which was 12.40% higher than expectations of -$0.97.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. AVTX’s latest balance sheet shows that the firm has $54.59M in Cash & Short Term Investments as of fiscal 2021. There were $32.83M in debt and $19.89M in liabilities at the time. Its Book Value Per Share was -$0.50, while its Total Shareholder’s Equity was $23.08M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AVTX is Buy with a score of 3.00.